Proactive Investors - Run By Investors For Investors

All WideCells divisions to start generating revenues after UK regulator approval

João Andrade, chief executive of WideCells Group PLC (LON:WDC), tells Proactive's Andrew Scott they've taken a significant step today towards becoming an end-to-end stem cell service company.

The group's been granted a licence by the UK's Human Tissue Authority, which allows them to import, export, process, store and distribute for treatment umbilical cord blood and tissue.

What in practice this official sanction does is allow them, under its brand name BabyCells, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe.

Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full WDC profile View Profile

WideCells Group Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use